Why is Gland Pharma falling/rising?

As of 17-Sep, Gland Pharma Ltd's stock price is currently at 1,986.95, reflecting a decrease of 34.35 points or 1.7%. Today's price summary indicates that the stock has underperformed its sector by 1.74%, with an intraday low of Rs 1973, marking a decline of 2.39%. Despite trading above its moving averages, the stock has experienced a significant drop in investor participation, with delivery volume falling by 30.55% compared to the 5-day average. Over the past year, Gland Pharma has managed to generate a return of 7.56%, which is notably higher than the negative return of -0.46% from the Sensex, although it has shown poor long-term growth with an annual operating profit decline of 5.32% over the last five years. In the broader market context, Gland Pharma's recent performance contrasts with the benchmark, as it has outperformed the BSE500 index, which has seen a negative return of -2.63% over the last year. However, the stock's high valuation, indicated by a Price to Book Value of 3.6 and a PEG ratio of 6.4, raises concerns about its sustainability, especially given the modest growth in profits of 6.7% over the same period. While the company benefits from a low debt-to-equity ratio and high institutional holdings, these positive factors are overshadowed by the risks associated with its expensive valuation and declining operating profits, contributing to the current downward movement in the stock price.